{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Naguib YW"],"funding":["NCI NIH HHS"],"pagination":["33-48"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5965255"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["In this study, a new compound, 4-(N)-docosahexaenoyl 2', 2'-difluorodeoxycytidine (DHA-dFdC), was synthesized and characterized. Its antitumor activity was evaluated in cell culture and in mouse models of pancreatic cancer. DHA-dFdC is a poorly soluble, pale yellow waxy solid, with a molecular mass of 573.3Da and a melting point of about 96°C. The activation energy for the degradation of DHA-dFdC in an aqueous Tween 80-based solution is 12.86kcal/mol, whereas its stability is significantly higher in the presence of vitamin E. NCI-60 DTP Human Tumor Cell Line Screening revealed that DHA-dFdC has potent and broad-spectrum antitumor activity, especially in leukemia, renal, and central nervous system cancer cell lines. In human and murine pancreatic cancer cell lines, the IC50 value of DHA-dFd"],"journal":["Neoplasia (New York, N.Y.)"],"pubmed_title":["Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity."],"pmcid":["PMC5965255"],"funding_grant_id":["R35 CA197627","R21 CA179362","R01 CA135274"],"pubmed_authors":["Lashinger LM","Aldayel AM","Hursting SD","Lansakara-P D","Cui Z","Valdes S","Niu M","Rodriguez BL","Peng L","Naguib YW"],"additional_accession":[]},"is_claimable":false,"name":"Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.","description":"In this study, a new compound, 4-(N)-docosahexaenoyl 2', 2'-difluorodeoxycytidine (DHA-dFdC), was synthesized and characterized. Its antitumor activity was evaluated in cell culture and in mouse models of pancreatic cancer. DHA-dFdC is a poorly soluble, pale yellow waxy solid, with a molecular mass of 573.3Da and a melting point of about 96°C. The activation energy for the degradation of DHA-dFdC in an aqueous Tween 80-based solution is 12.86kcal/mol, whereas its stability is significantly higher in the presence of vitamin E. NCI-60 DTP Human Tumor Cell Line Screening revealed that DHA-dFdC has potent and broad-spectrum antitumor activity, especially in leukemia, renal, and central nervous system cancer cell lines. In human and murine pancreatic cancer cell lines, the IC50 value of DHA-dFd","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jan","modification":"2025-04-05T10:58:51.953Z","creation":"2019-03-26T23:39:21Z"},"accession":"S-EPMC5965255","cross_references":{"pubmed":["26806350"],"doi":["10.1016/j.neo.2015.11.012"]}}